Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;237(3):420-430.
doi: 10.1097/XCS.0000000000000772. Epub 2023 May 25.

Delay and Disparity in Observed vs Predicted Incidence Rate of Screenable Cancer During the COVID-19 Pandemic

Kelsey S Romatoski  1 , Sophie H Chung, Kelly Kenzik, Gordana Rasic, Sing Chau Ng, Jennifer F Tseng, Teviah E Sachs
Affiliations

Delay and Disparity in Observed vs Predicted Incidence Rate of Screenable Cancer During the COVID-19 Pandemic

Kelsey S Romatoski et al. J Am Coll Surg. .

Abstract

Background: The COVID-19 pandemic resulted in disruption of healthcare services, including cancer screenings, yet data on this are limited. We sought to compare observed and expected cancer incidence rates for screenable cancers, quantifying potential missed diagnoses.

Study design: Lung, female breast, and colorectal cancer patients from 2010 to 2020 in the National Cancer Database were standardized to calculate annual incidence rates per 100,000. A linear regression model of 2010 through 2019 incidence rates (pre-COVID) was used to calculate predicted 2020 incidence compared with observed incidence in 2020 (COVID) with subanalyses for age, sex, race, ethnicity, and geographic region.

Results: In total, 1,707,395 lung, 2,200,505 breast, and 1,066,138 colorectal cancer patients were analyzed. After standardizing, the observed 2020 incidence was 66.888, 152.059, and 36.522 per 100,000 compared with the predicted 2020 incidence of 81.650, 178.124, and 44.837 per 100,000, resulting in an observed incidence decrease of -18.1%, -14.6%, and -18.6% for lung, breast, and colorectal cancer, respectively. The difference was amplified on subanalysis for lung (female, 65 or more years old, non-White, Hispanic, Northeastern and Western region), breast (65 or more years old, non-Black, Hispanic, Northeastern and Western region), and colorectal (male, less than 65 years old, non-White, Hispanic, and Western region) cancer patients.

Conclusions: The reported incidence of screenable cancers significantly decreased during the COVID-19 pandemic (2020), suggesting that many patients currently harbor undiagnosed cancers. In addition to the human toll, this will further burden the healthcare system and increase future healthcare costs. It is imperative that providers empower patients to schedule cancer screenings to flatten this pending oncologic wave.

PubMed Disclaimer

Comment in

References

    1. Bogani G, Signorelli M, Ditto A, Raspagliesi F. Surgical oncology at the time of COVID-19 outbreak. J Surg Oncol. 2020;122:115–116.
    1. Chen RC, Haynes K, Du S, et al. Association of cancer screening deficit in the United States with the COVID-19 pandemic. JAMA Oncol. 2021;7:878–884.
    1. Cancino RS, Su Z, Mesa R, et al. The impact of COVID-19 on cancer screening: challenges and opportunities. JMIR Cancer. 2020;6:e21697.
    1. Alkatout I, Biebl M, Momenimovahed Z, et al. Has COVID-19 affected cancer screening programs? A systematic review. Front Oncol. 2021;11:675038.
    1. Song H, Bergman A, Chen AT, et al. Disruptions in preventive care: mammograms during the COVID-19 pandemic. Health Serv Res. 2021;56:95–101.

Publication types

LinkOut - more resources